HLA associations in patients with polycystic ovaries and in patients with congenital adrenal hyperplasia caused by 21-hydroxylase deficiency.
Ninety-nine Caucasian patients with ultrasonically detected polycystic ovaries (PCO) were typed for human leucocyte (HLA) antigens. Fifty patients with congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency were similarly typed. Among the patients with PCO, there was a significant increase in the frequency of HLA DRW6 (P = 0.0027) compared with that found in a control population, which remained significant (P = 0.027) when corrected for the number of antigens tested. This difference was reduced, but remained significant (P = 0.006), when the patients with CAH and PCO were added. There was also a significant decrease in the frequency of HLA DR7 (P = 0.017) among the patients with PCO compared with a control population, but there was no distortion of the frequencies of HLA A, B or Cw antigens. Among the patients with CAH, previously well documented associations of HLA B14 and DR1 with non-classical disease were confirmed. The frequency of HLA Bw47 was increased among the whole group of CAH patients (P = 0.05) but was not increased among those with classical salt-wasting (SW) or simple virilizing (SV) disease. Family studies were performed in close female relatives of 16 of the PCO patients and 21 of the CAH patients but no evidence for genetic linkage between HLA and PCO status could be found. These data suggest that there is no significant component of disturbed adrenal steroid 21-hydroxylase activity to account for the PCO morphology, although there may be some other genetic factor, more proximal to the centromere on chromosome 6, affecting the development of polycystic ovaries.
Hague
W M
WM
Cobbold Laboratories, Middlesex Hospital, London, UK.
Adams
J
J
Algar
V
V
Drummond
V
V
Schwarz
G
G
Bottazzo
G F
GF
Jacobs
H S
HS
D000312:Adrenal Hyperplasia, Congenital / Q000150:complications / Q000209:etiology / Q000276:immunology*; D005190:Family; D005260:Female; D006680:HLA Antigens / Q000032:analysis*; D015235:HLA-B Antigens / Q000032:analysis; D015236:HLA-C Antigens / Q000032:analysis; D015798:HLA-DR1 Antigen / Q000032:analysis; D015808:HLA-DR6 Antigen / Q000032:analysis; D015809:HLA-DR7 Antigen / Q000032:analysis; D006801:Humans; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000276:immunology*
D006680:HLA Antigens; D015235:HLA-B Antigens; D015236:HLA-C Antigens; D015798:HLA-DR1 Antigen; D015808:HLA-DR6 Antigen; D015809:HLA-DR7 Antigen